Tinlarebant ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
301	黄斑ジストロフィー	2

301. 黄斑ジストロフィー

---

臨床試験数 : 46 /  薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05244304 (ClinicalTrials.gov)	March 28, 2022	20/1/2022	Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1	Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects	Stargardt Disease 1	Drug: Tinlarebant;Drug: Placebo	Belite Bio, Inc	NULL	Recruiting	12 Years	18 Years	All	60	Phase 3	China;France;Germany;Hong Kong;Netherlands;Switzerland;Taiwan;United Kingdom;Australia;Belgium;United States
2	NCT05266014 (ClinicalTrials.gov)	March 12, 2021	26/1/2022	This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease	Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease	Stargardt Disease	Drug: tinlarebant	RBP4 Pty Ltd	Belite Bio, Inc	Active, not recruiting	12 Years	18 Years	All	13	Phase 1/Phase 2	Australia;Taiwan